Effect of timing of vitamin B12 supplementation in patients receiving pemetrexed for treatment of advanced non-squamous non-small cell lung cancer or malignant pleural mesothelioma

Autor:	Zachary Schlei, Alison Meagher, Karen Pfentner, Grace K. Dy
Rok vydání:	2016
Předmět:	Oncology Cancer Research medicine.medical_specialty business.industry Pleural mesothelioma First line respiratory system medicine.disease respiratory tract diseases Pemetrexed Non squamous Internal medicine medicine In patient Vitamin B12 Non small cell business Lung cancer neoplasms medicine.drug
Zdroj:	Journal of Clinical Oncology. 34:e21682-e21682
ISSN:	1527-7755 0732-183X
DOI:	10.1200/jco.2016.34.15_suppl.e21682
Popis:	e21682Background: Pemetrexed (Pem) is a folate analog inhibitor considered first line (1L) for advanced non-squamous non-small cell lung cancer (NSCLC) and malignant pleural mesothelioma (MPM). Bef...
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_________::fe85acc4c65a2c80850f0a79601c7be2 https://doi.org/10.1200/jco.2016.34.15_suppl.e21682 Zobrazit plný text záznamu